CD274 and non-small cell lung carcinoma: While this could pose a challenge to the development of anti-miR-155 therapy, it also presents an opportunity, as elevated PD-L1 expression often positively correlates with the prognosis of patients receiving immune checkpoint inhibitors (ICIs) in NSCLC [15, 16].